Cost-effectiveness of i-Sleep, a guided online CBT intervention, for patients with insomnia in general practice: protocol of a pragmatic randomized controlled trial. by van der Zweerde, Tanja et al.
STUDY PROTOCOL Open Access
Cost-effectiveness of i-Sleep, a guided
online CBT intervention, for patients with
insomnia in general practice: protocol of a
pragmatic randomized controlled trial
Tanja van der Zweerde1,2* , Jaap Lancee3, Pauline Slottje2,4, Judith Bosmans5, Eus Van Someren6,7,
Charles Reynolds III8, Pim Cuijpers1,2 and Annemieke van Straten1,2
Abstract
Background: Insomnia is a highly prevalent disorder causing clinically significant distress and impairment. Furthermore,
insomnia is associated with high societal and individual costs. Although cognitive behavioural treatment for insomnia
(CBT-I) is the preferred treatment, it is not used often. Offering CBT-I in an online format may increase access. Many
studies have shown that online CBT for insomnia is effective. However, these studies have all been performed in general
population samples recruited through media. This protocol article presents the design of a study aimed at establishing
feasibility, effectiveness and cost-effectiveness of a guided online intervention (i-Sleep) for patients suffering from
insomnia that seek help from their general practitioner as compared to care-as-usual.
Methods/design: In a pragmatic randomized controlled trial, adult patients with insomnia disorder recruited through
general practices are randomized to a 5-session guided online treatment, which is called “i-Sleep”, or to care-as-usual.
Patients in the care-as-usual condition will be offered i-Sleep 6 months after inclusion. An ancillary clinician, known as the
psychological well-being practitioner who works in the GP practice (PWP; in Dutch: POH-GGZ), will offer online support
after every session. Our aim is to recruit one hundred and sixty patients. Questionnaires, a sleep diary and wrist actigraphy
will be administered at baseline, post intervention (at 8 weeks), and at 6 months and 12 months follow-up. Effectiveness
will be established using insomnia severity as the main outcome. Cost-effectiveness and cost-utility (using costs per
quality adjusted life year (QALY) as outcome) will be conducted from a societal perspective. Secondary measures are:
sleep diary, daytime consequences, fatigue, work and social adjustment, anxiety, alcohol use, depression and quality of life.
Discussion: The results of this trial will help establish whether online CBT-I is (cost-) effective and feasible in general
practice as compared to care-as-usual. If it is, then quality of care might be increased because implementation of i-Sleep
makes it easier to adhere to insomnia guidelines. Strengths and limitations are discussed.
Trial registration: Netherlands Trial register NTR 5202 (registered April 17st 2015).
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Background
Insomnia is a highly prevalent disorder, characterized by
difficulty initiating and/or maintaining sleep for at least
three nights per week for at least three months, causing
clinically significant distress or impairment in daily func-
tioning [1]. One third of the general population shows
symptoms of the disorder and about 10 % of the general
population meets all criteria of insomnia disorder [2].
The disorder often persists for years [3]. The economic
burden of insomnia is considerable; poor sleepers cost
around ten times more than good sleepers due to in-
creased healthcare use, work absenteeism and lower
work productivity [4, 5]. Insomnia is a significant prob-
lem in itself, but it is also associated with the develop-
ment of other problems. Patients suffering from
insomnia are at greater risk of developing comorbid
mental health problems such as depression and anxiety
[6–9] and of developing cardiovascular problems, con-
tributing to an increased mortality risk [10, 11].
The high prevalence and burden of insomnia calls for
(cost-) effective treatment. The most common treatment
for insomnia is medication; around 60 % of patients see-
ing their general practitioner (GP) with complaints of in-
somnia receive a prescription for benzodiazepines or
benzodiazepine-related medication [12, 13]. Meta-
analyses have demonstrated that benzodiazepines are ef-
fective in enhancing sleep in the short run, but have
negative side effects, e.g. headaches, drowsiness, dizzi-
ness, dependence [14, 15]. Furthermore, there is limited
evidence for the effects of sleep medication used in the
long run [16]. There is also little evidence that improve-
ment of sleep persists when sleep medication is with-
drawn [17].
Various non-pharmacological alternatives for the treat-
ment of insomnia are available. These treatments can be
classified as educational (psycho-education, sleep hy-
giene), behavioral (relaxation, sleep restriction, stimulus
control) or cognitive (paradoxical intention, identifying
and challenging dysfunctional thoughts about sleep)
[18–23]. Since the 1990s it has become popular to offer
those treatments in (various) combinations, referred to
as Cognitive Behavioral Therapy for Insomnia (CBT-I).
Several reviews have concluded that CBT-I is effective
and has longer lasting effects than medication. Even
though some side effects might occur in CBT-I, mainly
due to more pronounced fatigue because of sleep restric-
tion, those side effects usually pass quickly [24]. There-
fore, CBT-I is considered the preferred treatment for
insomnia [17, 20, 25–30] and is recommended in several
insomnia guidelines (e.g. NICE guidelines [31] and
Dutch guidelines [32]). Practice shows that there is a gap
between what is advocated by the guidelines (i.e.: CBT-I)
and what is offered in practice: despite considerable evi-
dence for the effectiveness of face-to-face CBT-I in
general practices [33], GPs tend to prescribe medication.
A possible reason is that GPs generally have insufficient
time or knowledge to provide the CBT-I themselves
[33]. Furthermore, there are not enough qualified psy-
chologists available to offer CBT-I. Online CBT-I may
provide a possible solution and enable GPs to offer pa-
tients accessible evidence-based treatment. During the
past decade, e-health has been introduced steadily into
mental healthcare. Many e-health programs have been
developed for different disorders [34–36]. Meta-analyses
have shown that these (guided) self-help programs, de-
fined largely as standardized therapies that patients work
through independently and at their own convenience
[37], are effective for a variety of mental health disorders
[38]. Meta-analyses on trials on self-help for insomnia
[39–42] have shown medium to large effects. A recent
meta-analysis showed that effect sizes for online CBT-I
were comparable to those of CBT-I delivered face-to-
face [43].
In general, e-health treatments are more effective
when delivered with some form of guidance or coaching
[40, 44, 45]. This guidance can be delivered by non-
specialists such as psychology students, nurses or psy-
chological wellbeing practitioners (PWP; in Dutch:
POH-GGZ). In the Netherlands almost every GP prac-
tice employs a PWP, usually a psychiatric nurse. This of-
fers an excellent opportunity to implement online
treatment for insomnia supported by PWPs in the gen-
eral practice.
The treatment to be investigated in the proposed
study, i-Sleep, proved to be feasible, acceptable and
effective [42]. However, in this previous study the par-
ticipants were recruited through a popular website
offering information on insomnia to the general public
(www.insomnie.nl). This may have resulted in a study
population that is, through self-selection, significantly
different (e.g., more highly motivated, more technology-
savvy) than patients turning to their GP for help. In the
proposed study, patients will be recruited via GP referral.
This means that we target a population of patients living
with insomnia disorder who are actively seeking help, i.e. a
representation of general practice. We will examine the
(cost-) effectiveness of online guided CBT-I (i-Sleep) from
a societal perspective in a direct comparison with
care-as-usual.
Aims and hypotheses
At the moment G.P. care for insomnia is mainly consist-
ing of sleep hygiene and prescribing medication and,
therefore, is often suboptimal, i.e. not adhering to guide-
lines. The objective of this pragmatic trial is to evaluate
the effectiveness and cost-effectiveness of an online
CBT-I intervention, i-Sleep, for patients with insomnia
in comparison with care-as-usual. Patients will receive
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online coaching by PWPs working in general practices.
We expect the intervention to improve the quality of
care for insomnia (i.e., lead to higher improvement rates
because more people receive care according to the
guideline) and to be cost-effective compared to care-as-
usual because of low intervention costs, less healthcare
utilization and less lost productivity. We expect that pa-
tients in the intervention group will show a reduction in
insomnia complaints and improved sleep parameters,
suffer fewer daytime consequences, and have lower costs
related to healthcare utilization and lost productivity
than patients in the care-as-usual group.
Methods/design
Study design
This study is a pragmatic randomized controlled trial
with an economic evaluation from a societal perspective
alongside. Patients referring to their GP with insomnia
are randomized to either the online intervention group,
who will gain access to the guided online intervention,
or the control group, who will receive G.P. care-as-usual
and will be offered the investigated guided online inter-
vention six months after inclusion. The study protocol,
information brochure, questionnaires, recruitment ma-
terial and informed consent form were approved by the
Medical Ethics Committee of the VU University Medical
Centre (METC VUmc, registration number 2015/258).
The trial is registered with the Netherlands Trial Regis-
ter (NTR 5202).
Inclusion and exclusion criteria
Patients aged 18 and over who turn to their GP for help
with insomnia complaints are evaluated for eligibility.
Inclusion criteria are assessed using a screening ques-
tionnaire (t0) and include: difficulty initiating or main-
taining sleep for at least 30 minutes a night, for at least
three nights a week, for at least three months, causing
clinically significant distress and/or impairment in daily
functioning, i.e. meeting criteria for a DSM-5 diagnosis
of insomnia [1]. Exclusion criteria are: no access to the
internet, inadequate proficiency in Dutch, meeting cri-
teria of the diagnosis of sleep apnea (assessed by the GP
and in the screening questionnaire using the Screening
for Sleeping disorders [46], pregnancy or breast feeding
during the trial, working in night shifts, psychological
treatment in the last six months, being suicidal (assessed
using 5 items from the MINI diagnostic interview [47]),
and schizophrenia or psychotic disorder (“Have you been
diagnosed with schizophrenia or psychosis?”, to which
participants reply ‘Yes’ or ‘No’). Other comorbid psycho-
logical disorders and somatic diseases are allowed. The
use of (sleep) medication is also allowed and tracked.
Recruitment
Patients are recruited through general practices. Recruit-
ment leaflets are distributed in waiting rooms, and GPs
are instructed to alert insomnia patients to the trial. Pa-
tients interested in participating are directed to a website
for more information and to leave their contact details.
Depending on speed of inclusion, we will also ask GPs
to contact patients that presented with insomnia in the
12 months before the start of the trial (database search).
Patients that enrol receive an email containing back-
ground information and a link to the screening ques-
tionnaire. If eligible, patients are sent an information kit
containing a study brochure, sleep diary, actigraphic
watch, informed consent form, and stamped return en-
velope to confirm participation. Patients complete the
baseline measurement by filling in a sleep diary and
wearing an actigraphic watch for a week. For a detailed
representation of participant flow in this trial, see Fig. 1.
Figure 1. Flowchart of the study design.
Randomization
After inclusion patients are randomized by an independ-
ent researcher using random sequence block
randomization (blocks of 2, 4 or 6), stratified by whether
or not they have used sleep medication in the past
4 weeks and by individual PWP, on a 1:1 ratio. After in-
clusion of a patient the independent researcher reveals
the next randomization outcome. Due to the nature of
the study, blinding of the researchers, PWPs or patients
is not possible.
The intervention: guided online intervention i-Sleep for
insomnia
The online intervention i-Sleep, developed at the Vrije
Universiteit Amsterdam (AS, JL, TZ), is based on a mix-
ture of self-help materials, research literature and inter-
views with patients. The treatment consists of online
lessons and includes the elements that are commonly in-
corporated in face-to-face CBT-I [19–23]. Initially the
treatment consisted of 6 lessons. Based on the first trial
on i-Sleep [42] we decided to combine the first two les-
sons (on psycho-education and sleep hygiene) into one
because most patients were already familiar with (part
of ) this information. The topics during the five lessons
are explained in Table 1. The intervention is offered with
online guidance from a coach. The aim of the feedback
is to comment on exercises, clarify information and mo-
tivate the patient to persist in carrying out the course
and the requested behavioral changes [44]. The coach
responds to every session the patient completes. We ad-
vise patients to do one lesson every week but they can
take some more time if needed. However, during this
study, coaching will stop 8 weeks after patients received
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login details even in case patients do not finish the en-
tire treatment.
Patients in the intervention condition will receive
guidance from a psychological wellbeing practitioner
(PWP) in each general practice, usually a (psychiatric)
nurse. We will provide training for the PWP in CBT-I as
well as in providing online feedback. The training will
consists of a 1.5 hour workshop, guided practice with
the online course and feedback training. PWPs will be
supervised by the first author (TZ) and an experienced
CBT psychologist. Patients in both conditions are also
allowed to receive care-as-usual from their GP or the
PWP.
Care-as-usual group
We will provide the participating GPs in our study with a
written version of the Dutch insomnia guidelines [32].
The core message of the guideline is formulated as: (1) the
preferred insomnia treatment is non-pharmacological, (2)
the GP might consider medication in exceptional situa-
tions, and only short term, (3) the preferred treatment for
short-term sleep problems is psycho-education and
Table 1 The session of online treatment i-Sleep
Session Content
1 Psycho-education, and sleep hygiene.
2 Stimulus control and sleep restriction: patients are taught to use the bedroom only to sleep and to get in and out of bed at the same time
every day. Furthermore they are asked to restrict this the time in bed to the average amount of night-time sleep. The initial sleep window
prescribed is based on sleep diary parameters over 7 nights, with a minimum of a 5 hour sleep window. When sleep efficiency (percentage
of time spent in bed that the person is asleep) is below 85 %, time in bed is restricted. Above 85 %, the sleep window can be lengthened.
Position of the sleep window is as patients prefer (going to bed later or getting up earlier). Daytime napping is discouraged. If unavoidable,
no longer than 30 minutes and not after dinner. Sleep restriction will be continued in session 3, 4 and 5 according to need.
3 Relaxation exercises and exercises to minimize worrying.
4 Dysfunctional cognitions about sleep are addressed: the basics of cognitive therapy are explained and the most common erroneous ideas
about insomnia are discussed.
5 Summary and plan for the future.
Enrolment Allocation Close-out
TIMEPOINT* t0 t1 t2 t3
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
i-Sleep 
intervention
Care-as-usual
ASSESSMENTS:
Online 
questionnaires 
(see table 2)
X X X X
Actigraphy X X X X
Sleep diary
X X X X
* t1, t2 and t3 are 8 weeks, 26 weeks and 52 weeks after baseline respectively.
Fig. 1 Schedule of enrolment, interventions, and assessments [75]
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information about sleep hygiene, (4) for longer term sleep
problems the preferred treatment is a combination of
stimulus-control, sleep restriction, relaxation and struc-
tured exercise [32]. We will not interfere with the care that
the GPs offer their patients. After online data collection,
we will extract information on consumption of GP-care
and prescription of medication from GP electronic re-
cords. Also, we will inquire from patients themselves how
many nights was medication used in the last week using
the sleep diary.
Assessments
Four assessments will take place: at baseline (T0),
8 weeks post-treatment (T1), 6- (T2) and 12-month (T3)
follow-up. For an overview of the measurements see
Table 2. Questionnaires will be administered online.
Additionally, participants will receive an actigraphic
watch and a sleep diary by mail at all assessments. Pa-
tients are asked to wear the actigraphic watch for 7 days
while also filling out the sleep diary for these same days
[48]. Additionally, data extracted from the electronic
medical records in general practice will be used to assess
consumption of care and prescription of sleep medica-
tion, up to 12 months follow-up.
Primary outcome: insomnia severity
The primary outcome of the study will be insomnia se-
verity as measured by the Insomnia Severity Index [49].
The ISI consists of 7 items scored on a 5-point Likert
scale (0 = not at all, 4 = extremely) and scores range from
0–28, higher scores indicating more severe insomnia.
The ISI assesses the nature, severity and the impact of
insomnia. Previous research has indicated that the
Insomnia Severity Index (ISI) is a valid and reliable in-
strument to quantify perceived insomnia severity and
presents a clinically useful tool in screening as well as
outcome measurement. It possesses adequate internal
consistency (Cronbach’s alpha = .90), is sensitive to
changes in perceived sleep difficulties over time [50] and
has been validated for online use [51]. We use a commu-
nity sample cut-off score of ≥10 to define clinical insom-
nia [50].
Secondary outcomes
Questionnaires
Daytime consequences suffered due to insomnia will be
measured using 6 items on the different domains men-
tioned in the DSM-5 diagnosis of insomnia disorder: en-
ergy, relationships, mood, concentration, productivity,
and sleepiness [52] rated on a 5-points scale at each
assessment phase (0 = not at all affected through to
4 = very much affected).
Daytime functioning will also be assessed using the 5-
item Work and Social Adjustment Scale [53]. Each of
the five items measure a domain of functioning: work,
home management, social leisure activities (i.e. with
others), private leisure activities (i.e. individually) and
ability to form and maintain close relationships with
others. For each domain of functioning the score ranges
from 1 through to 8, with higher scores indicating more
severe disruption. The internal consistency of the WSAS
ranges from Cronbach’s alpha 0.70 to 0.94 [53].
We will use the Fatigue Severity Scale [54], which con-
sists of 9 items, to measure fatigue. Each item is scored
on a 7-point Likert scale, ranging from 1 (strongly dis-
agree) through to 7 (strongly agree). Higher scores
Table 2 Measurements and instruments at different point of assessment
Measurement Instrument Baseline (T0) T1, T2 and T3 (at 8, 26 and 52 weeks)
Background characteristics n/a X -
History of insomnia n/a X
Alcohol use AUDIT X X
Insomnia severity ISI X X
Anxiety and depression HADS X X
Daytime insomnia consequences Espie et al., 2012 X X
Daytime functioning WSAS X X
Fatigue FSS X X
Quality of life EQ-5D-5 L X X
Healthcare utilization & work absenteeism TiC-P X X
Treatment satisfaction n/a - T1
Actigraphy Actigraph GT9X Link X X
Sleep diary Consensus diary X X
Sleep medication n/a X X
AUDIT: Alcohol Use Disorders Identification Test; ISI: Insomnia Severity Index; HADS: Hamilton Anxiety and Depression Scale; WSAS: Work and Social Adjustment
scale; FSS: Fatigue Severity Scale; EQ-5D-L: EuroQoL; TiC-P: Trimbos and iMTA questionnaire on Costs associated with Psychiatric Illness
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indicate more severe fatigue. This scale has shown an
excellent internal consistency and reliability (Cronbach’s
alpha of 0.93; [55]).
The Hospital Anxiety and Depression Scale consists of
14 items which are scored on a 4-point Likert scale each.
Seven items can be summed into a depression a score
and the other half into an anxiety score. Higher scores
represent more severe anxiety or depression [56]. The
HADS is a reliable and valid instrument also in Dutch
populations (Cronbach’s alpha of .88, [57]).
The Alcohol Use Disorders Identification Test ques-
tionnaire (AUDIT [58]), designed by the World Health
Organisation to screen for excessive alcohol consump-
tion, will be used to assess alcohol use, using a 5-point
Likert scale (higher scores indicating more alcohol use
and related issues). This instrument has a clear cut-off
value, is often used and well validated [58]. The total
score represents consumption level, dependence and
present alcohol-related harm. We will use the standard
cut-off of 8 to identify (but not exclude) heavy drinkers
which has shown to have good sensitivity and specificity
in detecting current social and medical problems related
to alcohol.
The EuroQol questionnaire (EQ-5D-5 L) [59] will be
used to measure health-related quality of life. Health
states will be converted to utility scores using the Dutch
EQ-5D-5 L tariff. Quality-adjusted life-years (QALYs)
will be calculated by multiplying the utility score of a
health state by the time spent in that health state.
Transitions between health states will be linearly
interpolated.
Diary and actigraphy
We will measure sleep estimates derived from both the
consensus sleep diary and the use of wrist actigraphy.
The sleep estimates are: Sleep Onset Latency (number of
minutes it takes to fall asleep after going to bed), Sleep
Efficiency (percentage of the total amount of time spent
in bed that is spent asleep), Number of Awakenings,
Wake After Sleep Onset (total minutes awake after sleep
onset), Total Sleep Time and Sleep Quality (a number
between 1 and 5 for each night). We will use the Dutch
translation of the consensus sleep diary [60] with some
minor text adaptations, achieved by consensus among a
group of Dutch sleep researchers.
In addition to the subjective sleep evaluations gathered
using the questionnaires and sleep diary, objective sleep
data will be collected using actigraphy. Actigraphic
watches, accelerometers recording motion over short
epochs, are non-invasive small devices worn on the non-
dominant wrist 24 hours a day. We will equip participants
with an Actigraph GT9X Link provided by ProCare, under
Actigraph Actilife 6 SmEnterprise licenses. The Actilife
software (http://www.actigraphcorp.com/solutions-and-
products/software/actilife/) will be used to extract the data
from the actigraphic watches. We will use a validated
script to calculate different sleep estimates: sleep period,
total sleep time, clock time falling asleep, wake up time,
percent sleep, wake after sleep onset, number of wake
bouts, fragmentation and latency [48, 61]. We will com-
pare the objective and subjective data.
Cost measures
Healthcare utilization will be assessed in two ways. First
we will use data derived from GP records. We will assess
the number of consultations with GPs, and general well-
being practitioners as well as medication prescriptions.
Next, we will ask the patients themselves which other
healthcare services they used (GP and other) and which
sleep and other medication they took. For this we will
use the TiC-P [62] (Hakkaart-van Roijen et al., 2002).
The Short Form Health and Labour Questionnaire
which is also part of the TiC-P will be used to measure
absenteeism from paid and unpaid work, and presentism
[62]. Healthcare utilization will be valued using Dutch
standard tariffs [63]. Costs associated with lost product-
ivity will be estimated according to the friction cost ap-
proach [64].
Adverse effects
We will investigate potential adverse effects. Adverse ef-
fects are defined as (1) worsening of sleep symptoms,
and (2) accidents. Adverse effects could be a result of
the insomnia disorder itself, but also potentially of the
sleep restriction exercise in i-Sleep. We will assess the
primary outcome measure in order to identify clinically
significant deterioration, e.g. exacerbation of insomnia
severity from pre- to post-treatment (ISI change score of
7 points or more [50]. Additionally, we will ask partici-
pants at post-test and follow-up 1 and 2 whether they
experienced a) falling incidents, b) traffic accidents, c)
any other negative events that they feel are related to fa-
tigue/sleepiness. Participants unavailable for post-test
and/or follow-up due to dropout will be asked these
questions via e-mail. The occurrence of adverse effects
in the intervention and in the care-as-usual condition
will be compared.
Sample size
In a previous RCT, the i-Sleep intervention demon-
strated an effect size of 1.06 on Sleep Quality (Pittsburgh
Sleep Quality Inventory, [42]). However, a recent meta-
analysis [40] on self-help for insomnia demonstrates
somewhat more modest effect sizes; a Hedges’ g of 0.80,
0.66 and 0.55 respectively for sleep efficiency, sleep onset
latency and wake after sleep onset at immediate post
treatment. For the current study we will use a conserva-
tive estimation of a post treatment effect size, a Cohen’s
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d of 0.50, on the primary outcome insomnia severity.
Using a power of 80 %, an alpha of 0.05, and a study
dropout rate of 20 %, we need to include 80 patients in
both conditions, 160 in total, to answer our primary re-
search question.
Statistical analysis
The study will be conducted in adherence to the Consol-
idated Standards of Reporting Trials (CONSORT; [65])
statement. For all analyses statistical significance will be
set at p < .05. In accordance with the intention-to-treat
principle, we will use all data independent of treatment
or study completion. Missing values will be imputed
using multiple imputation for calculation of Cohen’s d
[66, 67].
Between group interaction effects (time × group) will
be tested with Generalized Estimating Equations (GEE).
Variables that are not distributed equally or that predict
dropout will be added to the model as covariates. This
technique is suitable for the analysis of the longitudinal
relationship between a continuous outcome variable
and several time-dependent and time independent
covariates [68].
We will describe the magnitude of the effect (effect
size) with Cohen’s d. We will calculate this by dividing
the difference in scores of the two groups at post-test by
the pooled standard deviation of change scores (Cohen’s
d). This can thus be interpreted as the number of stand-
ard deviations the intervention group scores better than
the control group [69].
Next, we will compare the intervention and control
group with regard to the percentage of patients who
have (1) improved and (2) recovered. An ISI score of 10
or lower will be considered recovery. Improvement will
be defined as an ISI change score of 7 points or more
[50]. This information will be used to calculate the rela-
tive risk and the number needed to treat [70].
Cost-effectiveness and cost-utility analysis
Both cost-effectiveness and cost-utility analyses will be
performed. Cost-effectiveness analysis entails measuring
the value of the new therapy i-Sleep by calculating the
difference in costs between i-Sleep and care-as-usual,
and dividing this by the difference in effectiveness of
both treatment options (i.e., calculating the cost-
effectiveness ratio) [71, 72].
The cost-utility analysis represents the costs associated
with gaining one quality-adjusted life year (QALY).
Missing cost and effect data will be imputed using mul-
tiple imputation. Seemingly unrelated regression will be
used to estimate cost and effect differences while adjust-
ing for potential confounders. We will use bootstrapping
to estimate uncertainty surrounding the cost-
effectiveness estimates to account for the skewed
distribution of costs. Cost-effectiveness planes and cost-
effectiveness acceptability curves will be estimated to
show statistical uncertainty surrounding the cost-
effectiveness estimates.
Budget impact analysis (BIA)
A budget impact analysis (BIA) is used to calculate ex-
pected changes in the expenses if the new intervention
i-Sleep is adapted into the healthcare system. For the
BIA the population of people with insomnia will be esti-
mated using Dutch epidemiological data. We will ex-
trapolate the effectiveness of the treatments using a
Markov model based on the estimates obtained from the
proposed study. We will evaluate different implementa-
tion scenarios (0 %, 50 %, 100 %, subgroups only).
Aggregated and disaggregated (e.g. GP/PWP care, sec-
ondary care, and productivity losses) total costs per year
will be presented for the different perspectives and sce-
narios. We expect that the intervention will lead to
increased work productivity in comparison to care-as-
usual, and that the largest economic benefits generated
by the intervention are related to reduced productivity
losses. Costs associated with the treatment condition are
costs of the use of the intervention platform, and
invested time of the PWPs.
Discussion
Insomnia is associated with high personal and societal
costs, while the first treatment of choice (CBT-I) is often
unavailable. Guided online CBT-I might be a solution.
The efficacy of online CBT-I has already been estab-
lished but an important limitation of those studies is that
they are mainly performed in general population samples
[73], in which patients might be more motivated or
more familiar with the internet than the average insom-
nia patient who seeks help in the GP practice. To our
knowledge, this is the first study performed in general
practice thus allowing for generalizability to routine
care. Our first aim is to study the effects on insomnia se-
verity and sleep parameters, but also on fatigue, mental
health and daytime consequences. Moreover we will
compare the cost-effectiveness from a societal perspec-
tive between the guided online intervention and care-as-
usual in GP practice.
Strengths and weaknesses
The five major strengths of this study are the fact that a)
it is a trial conducted in general practice, where most
people with insomnia first turn for help, and where care
can be improved; b) we will use objective sleep data
through actigraphic watches as well as subjective data
through sleep diaries; c) we use an array of outcome
measures not only examining sleep itself but also the
consequences on mood, anxiety, fatigue and day-time
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functioning; d) we will examine possible negative effects
due to the online intervention and e) we are assessing
not only effectiveness but also cost-effectiveness, in a
real-life setting of high external validity. The sample will
likely be of higher heterogeneity than is the case in stud-
ies that recruit participants through a website and will
tell us whether this form of treatment is feasible in rou-
tine care.
Conducting the trial in general practice ensures that
our conclusions will be generalizable to the average pa-
tient consulting their GP with sleep problems. Also,
guidance can be provided by a psychiatric nurse or
PWP. This could (partly) solve the current issue of GPs
lacking time and knowledge to deliver CBT-I and the
limited availability of trained psychologists. At the same
time, the study provides a true test of whether our inter-
vention i-Sleep can be implemented in general practice
and therefore be disseminated to a much wider array of
patients. We expect to find that i-Sleep can be imple-
mented and provide an alternative to care-as-usual that
is more effective in the long term, that is cost-effective,
comes with fewer problems such as side-effects and de-
pendence compared to medication, and is well accepted
by both the patient and healthcare providers (GP and
PWP).
There are also potential weaknesses in our study. First
of all, it might be a weakness that our intervention lacks
any face-to-face contact. We might also have chosen to
offer the treatment in blended format where patients re-
ceive a combination of online and face-to-face therapy.
Blended care might be more acceptable to the patient as
well as the professionals and it has been suggested to be
effective in other disorders, e.g. depression [74]. How-
ever, for this trial we chose not to blend care, because a
purely online treatment was deemed more feasible, more
cost-effective and easier to implement. A second poten-
tial weakness is that we include a convenience sample of
GPs. The participating GPs might be more interested in
insomnia than those who do not participate. This means
that care-as-usual might be of higher quality than pro-
vided on average. Also, the participating GPs offer access
to a mostly urban population. A third potential weakness
is that we include professionals (PWPs) who are cur-
rently employed by GPs but who have varying levels of
expertise in insomnia and online treatments. Even
though we will train the PWPs, and we will supervise
them during the trial, it may lead to heterogeneity in the
way treatments are delivered. In other words, the high
external validity may lead to less internal validity.
Another potential limitation is the fact that we do not
establish the DSM diagnosis based on clinical interviews.
Patients are referred to us by the GP who establishes
clinically relevant sleep problems. The sleep diary, acti-
graphy and ISI provide us with further information
about the severity of the insomnia. Using online ques-
tionnaires eliminates the risk of interviewer bias and it
ensures relatively easy follow-up measurements while
minimizing the burden for participants.
Also, it may be a disadvantage that participants do not
gain access to the online treatment immediately: the trial
involves a series of practical steps and registration that
take some time between enrollment and actual participa-
tion. This may influence patients’ motivation negatively.
In summary, online CBT for insomnia might be a
cost-effective alternative to care-as-usual, and the pro-
posed study aims to establish that online guided inter-
vention such as our i-Sleep module can be successfully
used in primary care. The availability of a web-based
intervention could be an innovative way for GPs to ad-
here to the insomnia guidelines and offer patients opti-
mal care while efficiently using limited resources.
Trial status
The first participants are being recruited.
Availability of Data and Materials
Collected data will be made accessible (without com-
promising anonymity) at the end of the data collection
phase.
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